These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38648580)

  • 1. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
    Rosso M; Gonzalez CT; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2020 Jun; 7(6):945-955. PubMed ID: 32452160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
    Bar-Or A; Montalban X; Hu X; Kropshofer H; Kukkaro P; Coello N; Ludwig I; Willi R; Zalesak M; Ramanathan K; Kieseier BC; Häring DA; Bagger M; Fox E
    Neurol Ther; 2023 Feb; 12(1):303-317. PubMed ID: 36534274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring treatment response to advance precision medicine for multiple sclerosis.
    Calabresi PA; Kappos L; Giovannoni G; Plavina T; Koulinska I; Edwards MR; Kieseier B; de Moor C; Sotirchos ES; Fisher E; Rudick RA; Sandrock A
    Ann Clin Transl Neurol; 2021 Nov; 8(11):2166-2173. PubMed ID: 34704393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
    Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
    Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
    Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of radiologic disease activity by serum neurofilaments in MS.
    Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Johnsson M; Stenberg YT; Farman HH; Blennow K; Zetterberg H; Malmeström C; Sandgren S; Rosenstein I; Lycke J; Axelsson M; Novakova L
    Mult Scler; 2024 May; 30(6):664-673. PubMed ID: 38481083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
    Proschmann U; Haase R; Inojosa H; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():715195. PubMed ID: 34512637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
    Kaufman M; Cree BA; De Sèze J; Fox RJ; Gold R; Hartung HP; Jeffery D; Kappos L; Montalbán X; Weinstock-Guttman B; Ticho B; Duda P; Pace A; Campagnolo D
    J Neurol; 2015 Feb; 262(2):326-36. PubMed ID: 25381458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.